CYTOO SA: ReferenceCell Platform for Improved High Content Screening will be Assessed by Leading Industry Consortium

NEEDHAM, Mass. & GRENOBLE, France--(BUSINESS WIRE)--The Drug Safety Executive Council (DSEC), an industry membership run by Cambridge Healthtech Associates (CHA), together with CYTOO, a provider of innovative products for the life science research and drug discovery markets with an emphasis in cell based assays, high content analysis and cell screening, today announced a new program as part of DSEC’s Technology Evaluation Consortium.